Nature Communications (Jun 2020)
The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
- Keliang Wang,
- Jie Luo,
- Shuyuan Yeh,
- Bosen You,
- Jialin Meng,
- Philip Chang,
- Yuanjie Niu,
- Gonghui Li,
- Changxue Lu,
- Yezi Zhu,
- Emmanuel S. Antonarakis,
- Jun Luo,
- Chi-Ping Huang,
- Wanhai Xu,
- Chawnshang Chang
Affiliations
- Keliang Wang
- Department of Urology, The 4th Affiliated Hospital of Harbin Medical University, NHC Key Lab of Molecular Probes and Targeted Diagnosis and Therapy
- Jie Luo
- George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center
- Shuyuan Yeh
- George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center
- Bosen You
- Department of Urology, The 4th Affiliated Hospital of Harbin Medical University, NHC Key Lab of Molecular Probes and Targeted Diagnosis and Therapy
- Jialin Meng
- George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center
- Philip Chang
- Department of Neurology, Kaiser Permanente Santa Clara Medical Center
- Yuanjie Niu
- Tianjin Institute of Urology, Tianjin Medical University
- Gonghui Li
- Department of Urology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine
- Changxue Lu
- Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, and James Buchanan Brady Department of Urology, Johns Hopkins University School of Medicine
- Yezi Zhu
- Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, and James Buchanan Brady Department of Urology, Johns Hopkins University School of Medicine
- Emmanuel S. Antonarakis
- Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, and James Buchanan Brady Department of Urology, Johns Hopkins University School of Medicine
- Jun Luo
- Prostate Cancer Program, Sidney Kimmel Comprehensive Cancer Center, and James Buchanan Brady Department of Urology, Johns Hopkins University School of Medicine
- Chi-Ping Huang
- Sex Hormone Research Center, Department of Urology, China Medical University and Hospital
- Wanhai Xu
- Department of Urology, The 4th Affiliated Hospital of Harbin Medical University, NHC Key Lab of Molecular Probes and Targeted Diagnosis and Therapy
- Chawnshang Chang
- George Whipple Lab for Cancer Research, Departments of Pathology, Urology, Radiation Oncology, and The Wilmot Cancer Institute, University of Rochester Medical Center
- DOI
- https://doi.org/10.1038/s41467-020-15396-5
- Journal volume & issue
-
Vol. 11,
no. 1
pp. 1 – 14
Abstract
Castration resistant prostate cancer patients treated with enzalutamide may develop resistance to the drug. Here, the authors report that monoamine oxidase-A expression is increased in these resistant tumors and that the antidepressants phenelzine/clorgyline can reverse such resistance to further suppress tumor growth
